Charles River Laboratories International, Inc.
278.35USD
-2.4100 (-0.86%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 4.0B | 4.1B | 4.0B | 4.0B | 3.9B | 4.0B |
| Q1 | 913.9M | 1.0B | 1.0B | 984.2M | 995.8M | — |
| Q2 | 973.1M | 1.1B | 1.0B | 1.0B | 1.0B | — |
| Q3 | 989.2M | 1.0B | 1.0B | 1.0B | 959.0M | — |
| Q4 | 1.1B* | 1.0B* | 1.0B* | 994.2M* | 952.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 9.48 | 9.22 | .200 | -2.91 | 11.32 | 12.69 |
| Q1 | 1.81 | 2.01 | 1.30 | .500 | -.300 | — |
| Q2 | 2.13 | 1.89 | 1.74 | 1.06 | -.030 | — |
| Q3 | 1.88 | 1.69 | 1.33 | 1.10 | 2.95 | — |
| Q4 | 3.65* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 3.64* |
| -4.15* |
| -5.58* |
| 3.31 |
| — |